Abstract A097: Racial and ethnic disparities in risk of persistent opioid use in a diverse cohort of breast cancer survivors and matched women without cancer
Authors: Chen Lie Hong , Hechter Rulin C. , Shi Jiaxiao , Gu Zheng , Brady-Rogers Moira , Chlebowski Rowan T. , Hague Reina 
Published: September 2024

Abstract
Background: Persistent opioid use (POU) in breast cancer survivors after they have completed active cancer treatment is an emerging area of concern. Disparities affecting the risk of POU remains understudied in breast cancer survivors. We evaluated disparities in examining the risk with POU in breast cancers survivors in the year after active cancer treatment along with a comparison group. Methods: We assembled a cohort of 14,347 female breast cancer (BC) survivors diagnosed in 2009-2019 treated for early-stage disease (in situ, local, regional), who had at least two opioid prescriptions after one year of survivorship and 51,369 age-matched women without cancer. Data were captured from the tumor registry, electronic health records, and pharmacy databases. The primary outcome was POU defined as continuously receiving at least 90 days supplies of opioids during follow-up. Patients were followed through the date once they met POU criteria, died, disenrolled from health plan, or reached study’s end (12/31/2021), whichever came first. We used the multivariable proportional hazard regression to estimate the association [hazard ratios (HR), 95% confidence interval (CI)] between race ethnicity and POU. Results: Overall, the cohort was diverse: 7% Asian/Pacific Islander (API); 14% Black; 28% Hispanic; and 50% White women. During a median follow-up of 6.4 years, 11134 (17%) women developed POU. Patients who developed POU had longer annualized median opioid duration, especially in Black patients (175 vs. 5 days) and were prescribed stronger opioids [median maximum daily morphine milligram equivalent (62.5 vs 42.9)], compared to those who did not develop POU. In the multivariable analyses adjusted for sociodemographic characteristics, opioid type, and other pain medications, Black, Hispanic and API women were 28%, 42% and 54% less likely to develop POU compared to White women [HR (95%CI): 0.72 (0.68-0.76), 0.58 (0.55-0.61), and 0.46 (0.42-0.52), respectively]. However, Black women were only 19% less likely [HR (95%CI): 0.81(0.72-0.92)] to develop POU compared to White women in BC survivors. Also, patients with older age, Elixhauser Comorbidity Index ≥3; smoking, type of opioid (Oxycodone and hydrocodone), and who used other psychiatric and pain medications had significantly greater POU risk. Conclusion: Findings suggest that women of color were less likely to develop POU. Further studies will include further examining clinical and pharmacological management which might have played a role in the race ethnicity groups.
Citation Format: Lie Hong Chen, Rulin C. Hechter, Jiaxiao Shi, Zheng Gu, Moira Brady-Rogers, Rowan T. Chlebowski, Reina Hague. Racial and ethnic disparities in risk of persistent opioid use in a diverse cohort of breast cancer survivors and matched women without cancer [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr A097.